IMpower150 first showed benefits of ICIs on EGFR mutation‐positive NSCLC patients, with improved PFS (10.2 vs. 7.1 months) in atezolizumab plus bevacizumab and chemotherapy group compared with bevacizumab and chemotherapy combination group in EGFR mutation‐positive NSCLC patients.345. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.